Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

View:
Post by Ingiboy on Mar 27, 2024 12:07pm

Buyout

It will be interesting to see if Andrew and whoever else is involved with this Take-Over Bid will stay with this proposal in light of the negative response or will they restructure it and come back with a conventional Buyout ?
Many questions arise if we see an actual buyout proposal:

1. How many shares would have to be bought out ?  How many existing shareholders would be part of the new company and as such would not be bought out ? My guess is that at least 20,000,000 would have to be bought out.
2. What would be the buyout price ?  We all would like to see RPINVESTOR1's and Bluemoon20's price of $2.00+ but realistically that would be for example 20,000,000 x $2.00 = $40,000,000.  Does this group have the capability of raising that kind of money ?  

I will ask the question of all of you:  what is your buyout price ?
Comment by Bellend2 on Mar 27, 2024 12:09pm
This post has been removed in accordance with Community Policy
Comment by Ingiboy on Mar 28, 2024 12:21pm
Bellend2, I hope this is not a "done deal".   I am sure that Andrew contacted all major shareholders to see if they would vote yes on this proposal before launching it.  That is what scares me and supports your theory that it is a done deal. On the other hand we need to remember he needs 66 2/3% approval to pull this off and that may be tough. If it is rejected and he truly ...more  
Comment by Bellend2 on Mar 28, 2024 1:24pm
This post has been removed in accordance with Community Policy
Comment by RPINVESTOR1 on Mar 28, 2024 12:08pm
Ingiboy:- The present offer to purchase would give shareholders a maximum of $0.16 USD per share (1 share x 8% x $2.00 USD). Shiseido - if interested - could offer say $0.25 USD per share. Would the CEO then use the 'poison pill' or some other strategy to benefit himself? Also, if Shiseido does not make an offer soon I think that we can conclude that they were not too impressed with the ...more  
Comment by Ingiboy on Mar 28, 2024 2:24pm
RPINVESTOR1, I need to see if I can find in the Replicel News archives the N/R regarding the "Poisen Pill" and how it was presented. As far as Shiseido I still am puzzled as to why they went to such great lengths and expense to fight Replicel and in so doing protect their right to proceed with their version of RCH-01 in Asia.  If they were not thrilled with the results of the second ...more  
Comment by RPINVESTOR1 on Mar 28, 2024 3:20pm
Yes, I would also reluctantly vote for it ('A bird in the hand is worth 2 in the bush.'). As I recall the poison pill would automatically double the number of shares each shareholder owns.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities